Firstline Keytruda shows better overall survival in head & neck cancer

First-line Keytruda shows better overall survival in head & neck cancer

07:41 EDT 23 Oct 2018 | Pharmafile

MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new Phase 3 data into its efficacy in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), revealing it met its primary endpoint.

In patients whose tumours expressed PD-L1 with a combined positive score (CPS) of at least 20, the findings demonstrated that, when used as a monotherapy, Keytruda improved overall survival (OS) rates by 39% compared to the EXTREME regimen of Merck KGaA’s Erbitux (cetuximab) plus ci

read more

Original Article: First-line Keytruda shows better overall survival in head & neck cancer

More From BioPortfolio on "First-line Keytruda shows better overall survival in head & neck cancer"